Cancer Gene Therapy Market Analysis

Description: The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer.

The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.

A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.

Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.

Cancer Gene Therapy Report Highlights & Findings:
- Highest Number of Drugs in Preclinical Stage: 37
- Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100
- Significance of Oncology Therapeutics in Gene Therapy
- Current Applications of Gene Therapy to Cancer Treatment
- Favorable Parameters for Cancer Gene Therapy
- Issued Involved with Application of Gene Therapy in Cancer Patients
- Regulatory Scenario for Gene Therapy Market
- Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

Contents:
1. Introduction to Gene Therapy
   1.1 History of Gene Therapy
   1.2 Vectors of Gene Therapy

2. Global Gene Therapy Market
   2.1 Market Overview
   2.2 Emerging Trends in Gene Therapy

3. Significance of Cancer Therapeutics in Gene Therapy

4. Current Applications of Gene Therapy to Cancer Treatment
   4.1 Cancer Treatments Currently Available
   4.2 Approaches to Cancer Gene Therapy
   4.3 Gene Therapy Used in Cancer Treatment
   4.4 Methods of Inserting Genes into Cancer Patients

5. Cancer Gene Therapy Market Dynamics
   5.1 Favorable Parameters for Cancer Gene Therapy
   5.2 Issued Involved with Application of Gene Therapy in Cancer Patients
   5.3 Cancer Gene Therapy Clinical Insight
6. Regulatory Scenario for Gene Therapy Market
   6.1 EU
   6.2 US

7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
   7.1 Unknown Phase
   7.2 Research
   7.3 Preclinical
   7.4 Phase I/II
   7.5 Phase II
   7.6 Phase III

8. Marketed Cancer Gene Therapy Drugs

9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline
   9.1 No Development Reported
   9.2 Discontinued
   9.3 Suspended

10. Competitive Landscape
    10.1 Advantagene
    10.2 BioCancell
    10.3 Celgene
    10.4 Cell Genesys
    10.5 Epeius Biotechnologies
    10.6 GenVec
    10.7 Introgen Therapeutics
    10.8 MultiVir
    10.9 ZIOPHARM Oncology
    10.10 Shenzhen SiBiono GeneTech

List Of Figures:

Figure 3-1: Gene Therapy by Indication
Figure 5-1: Favorable Parameters for Cancer Gene Therapy
Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2775728/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Cancer Gene Therapy Market Analysis
- **Web Address:** [http://www.researchandmarkets.com/reports/2775728/](http://www.researchandmarkets.com/reports/2775728/)
- **Office Code:** SCD23G2X

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy</td>
<td>✅</td>
<td>USD 1980 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td>USD 2200 - Until 10th Jul 2016</td>
<td></td>
</tr>
<tr>
<td>CD-ROM</td>
<td>✅</td>
<td>USD 1800 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td>USD 2000 - Until 10th Jul 2016</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>✅</td>
<td>USD 1620</td>
</tr>
<tr>
<td>Single User</td>
<td>USD 1800 - Until 10th Jul 2016</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>✅</td>
<td>USD 3240</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 3600 - Until 10th Jul 2016</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:**
  - Mr 🅱️
  - Mrs 🅱️
  - Dr 🅱️
  - Miss 🅱️
  - Ms 🅱️
  - Prof 🅱️
- **First Name:** _______________________________  **Last Name:** _______________________________
- **Email Address:** _______________________________
- **Job Title:** _______________________________
- **Organisation:** _______________________________
- **Address:** _______________________________
- **City:** _______________________________
- **Postal / Zip Code:** _______________________________
- **Country:** _______________________________
- **Phone Number:** _______________________________
<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
</table>

Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World